SG162605A1 - Pharmaceutical compositions - Google Patents
Pharmaceutical compositionsInfo
- Publication number
- SG162605A1 SG162605A1 SG200501782-7A SG2005017827A SG162605A1 SG 162605 A1 SG162605 A1 SG 162605A1 SG 2005017827 A SG2005017827 A SG 2005017827A SG 162605 A1 SG162605 A1 SG 162605A1
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical compositions
- pharmaceutically acceptable
- valsartan
- bioavailable
- hydrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59968700A | 2000-06-22 | 2000-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG162605A1 true SG162605A1 (en) | 2010-07-29 |
Family
ID=24400655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200501782-7A SG162605A1 (en) | 2000-06-22 | 2001-06-20 | Pharmaceutical compositions |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP1296677A2 (fr) |
JP (3) | JP2003535895A (fr) |
KR (2) | KR100659644B1 (fr) |
CN (2) | CN100450478C (fr) |
AU (2) | AU8576801A (fr) |
BR (1) | BR0111868A (fr) |
CA (1) | CA2411882C (fr) |
CZ (1) | CZ20024180A3 (fr) |
EC (1) | ECSP024389A (fr) |
HK (2) | HK1052868A1 (fr) |
HU (1) | HUP0301390A3 (fr) |
IL (2) | IL153428A0 (fr) |
MX (1) | MXPA02012683A (fr) |
NO (1) | NO20026123L (fr) |
NZ (2) | NZ540748A (fr) |
PL (1) | PL358290A1 (fr) |
RU (1) | RU2333757C2 (fr) |
SG (1) | SG162605A1 (fr) |
SK (1) | SK18062002A3 (fr) |
WO (1) | WO2001097805A2 (fr) |
ZA (1) | ZA200210359B (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ293257B6 (cs) * | 1998-12-23 | 2004-03-17 | Novartis Ag | Farmaceutický přípravek obsahující antagonistu receptoru AT1 pro léčení nemocí spojených s nárůstem receptorů AT1 v subepiteliální vrstvě |
BRPI0306907B8 (pt) * | 2002-01-17 | 2021-05-25 | Novartis Ag | composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais |
US7468390B2 (en) | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
TWI299663B (en) * | 2002-05-14 | 2008-08-11 | Novartis Ag | Methods of treatment |
KR100882156B1 (ko) * | 2003-08-08 | 2009-02-06 | 아지노모토 가부시키가이샤 | 나테글리니드 함유 제제 |
WO2006021443A2 (fr) * | 2004-08-26 | 2006-03-02 | Novartis Ag | Composes organiques |
SI2033629T1 (sl) | 2004-12-24 | 2013-01-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Trden farmacevtski sestavek, ki obsega valsartan |
JP2009001520A (ja) * | 2007-06-21 | 2009-01-08 | Kowa Co | ジフェンヒドラミン含有固形製剤 |
RU2487710C2 (ru) | 2007-10-09 | 2013-07-20 | Новартис Аг | Фармацевтическая композиция валсартана |
WO2009059605A1 (fr) * | 2007-11-08 | 2009-05-14 | University Of Copenhagen | Tri de solides à petite échelle |
EP2067470A1 (fr) * | 2007-12-03 | 2009-06-10 | Laboratorios Lesvi, S.L. | Compositions pharmaceutiques contenant du valsartan et procédé pour sa préparation |
WO2011102702A2 (fr) | 2010-02-16 | 2011-08-25 | Krka, D. D., Novo Mesto | Procédé pour la préparation de formes posologiques solides orales comprenant du valsartan |
CN102362865B (zh) * | 2011-10-28 | 2013-06-26 | 山东司邦得制药有限公司 | 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用 |
WO2013098576A1 (fr) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Composition pharmaceutique de valsartan à libération immédiate |
WO2013098578A1 (fr) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Composition pharmaceutique d'hydrochlorothiazide de valsartan à libération immédiate |
CN103599084B (zh) * | 2013-11-22 | 2018-10-30 | 威海迪素制药有限公司 | 一种降压组合物 |
CN112807286A (zh) * | 2021-01-20 | 2021-05-18 | 海南皇隆制药股份有限公司 | 一种缬沙坦分散片制备方法和缬沙坦分散片 |
CN112826806A (zh) * | 2021-01-20 | 2021-05-25 | 海南皇隆制药股份有限公司 | 一种缬沙坦片制备方法和缬沙坦片 |
EP4295839A1 (fr) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combinaison de valsartan et d'indapamide |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049394A2 (fr) * | 1996-06-27 | 1997-12-31 | Novartis Ag | Formes posologiques solides de valsartan administrees par voie orale |
WO2000038676A1 (fr) * | 1998-12-23 | 2000-07-06 | Novartis Ag | Utilisation d'un antagoniste du recepteur d'at-1 ou d'un modulateur du recepteur d'at-2 pour traiter des affections associees a une augmentation des recepteurs d'at-1 ou d'at-2 |
WO2001076573A2 (fr) * | 2000-04-12 | 2001-10-18 | Novartis Ag | Combinaison de composés organiques |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122007000050I1 (de) | 1990-02-19 | 2007-11-08 | Novartis Ag | Acylverbindungen |
JPH09510225A (ja) * | 1994-03-17 | 1997-10-14 | チバ−ガイギー アクチェンゲゼルシャフト | バルサルタンを用いる糖尿病性ネフロパシーの治療 |
BR9611007A (pt) * | 1995-10-06 | 1999-07-13 | Novartis Ag | Antagonistas do receptor at1 para prevenir e tratar a deficiência renal pós-isquêmica e para a proteção de rins isquêmicos |
DE69718146T2 (de) * | 1996-02-29 | 2003-10-02 | Novartis Ag | At1 rezeptor antagonist zur anregung von apoptosis |
EP0904060B1 (fr) * | 1996-05-20 | 2003-12-10 | Janssen Pharmaceutica N.V. | Compositions antifongiques avec biodisponibilite amelioree |
US6541669B1 (en) * | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
-
2001
- 2001-06-20 CZ CZ20024180A patent/CZ20024180A3/cs unknown
- 2001-06-20 CN CNB2005100510503A patent/CN100450478C/zh not_active Expired - Fee Related
- 2001-06-20 CA CA2411882A patent/CA2411882C/fr not_active Expired - Fee Related
- 2001-06-20 SG SG200501782-7A patent/SG162605A1/en unknown
- 2001-06-20 BR BR0111868-4A patent/BR0111868A/pt not_active Application Discontinuation
- 2001-06-20 NZ NZ540748A patent/NZ540748A/en not_active IP Right Cessation
- 2001-06-20 MX MXPA02012683A patent/MXPA02012683A/es active IP Right Grant
- 2001-06-20 KR KR1020057013346A patent/KR100659644B1/ko not_active IP Right Cessation
- 2001-06-20 AU AU8576801A patent/AU8576801A/xx active Pending
- 2001-06-20 JP JP2002503289A patent/JP2003535895A/ja not_active Withdrawn
- 2001-06-20 NZ NZ522953A patent/NZ522953A/en not_active IP Right Cessation
- 2001-06-20 WO PCT/EP2001/006983 patent/WO2001097805A2/fr active Search and Examination
- 2001-06-20 HU HU0301390A patent/HUP0301390A3/hu not_active Application Discontinuation
- 2001-06-20 IL IL15342801A patent/IL153428A0/xx unknown
- 2001-06-20 RU RU2003100507/15A patent/RU2333757C2/ru not_active IP Right Cessation
- 2001-06-20 AU AU2001285768A patent/AU2001285768B2/en not_active Ceased
- 2001-06-20 SK SK1806-2002A patent/SK18062002A3/sk unknown
- 2001-06-20 CN CNB018115527A patent/CN1221256C/zh not_active Expired - Fee Related
- 2001-06-20 EP EP01965014A patent/EP1296677A2/fr not_active Ceased
- 2001-06-20 PL PL01358290A patent/PL358290A1/xx not_active Application Discontinuation
- 2001-06-20 EP EP09004205A patent/EP2072049A3/fr not_active Withdrawn
- 2001-06-20 KR KR10-2002-7017469A patent/KR100525341B1/ko not_active IP Right Cessation
-
2002
- 2002-12-12 EC EC2002004389A patent/ECSP024389A/es unknown
- 2002-12-12 IL IL153428A patent/IL153428A/en not_active IP Right Cessation
- 2002-12-19 NO NO20026123A patent/NO20026123L/no unknown
- 2002-12-20 ZA ZA200210359A patent/ZA200210359B/xx unknown
-
2003
- 2003-07-08 HK HK03104842.9A patent/HK1052868A1/zh unknown
-
2006
- 2006-03-20 HK HK06103477.0A patent/HK1083452A1/xx unknown
-
2007
- 2007-01-11 JP JP2007003546A patent/JP2007091758A/ja not_active Withdrawn
-
2012
- 2012-08-02 JP JP2012172246A patent/JP2012211200A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049394A2 (fr) * | 1996-06-27 | 1997-12-31 | Novartis Ag | Formes posologiques solides de valsartan administrees par voie orale |
WO2000038676A1 (fr) * | 1998-12-23 | 2000-07-06 | Novartis Ag | Utilisation d'un antagoniste du recepteur d'at-1 ou d'un modulateur du recepteur d'at-2 pour traiter des affections associees a une augmentation des recepteurs d'at-1 ou d'at-2 |
WO2001076573A2 (fr) * | 2000-04-12 | 2001-10-18 | Novartis Ag | Combinaison de composés organiques |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG162605A1 (en) | Pharmaceutical compositions | |
CA2378469A1 (fr) | Composition orale solide comprenant de la carbidopa, de la levodopa et de l'entacapone | |
CA2427815A1 (fr) | Preparations d'hydrocodone a liberation lente | |
HUP0302086A2 (hu) | Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására | |
CA2339991A1 (fr) | Microemulsions comme formes pharmaceutiques solides destinees a une administration orale | |
WO2001085257A3 (fr) | Compositions d'antagoniste opioide et formes de dosage | |
HUP0302319A3 (en) | Pharmaceutical composition for oral administration of active ingredient | |
IL150696A0 (en) | Pharmaceutical compositions containing benzimidazole derivatives and processes for the manufacture thereof | |
AU2001263229A1 (en) | Compositions and methods for administration of pharmacologically active compounds | |
WO2001042219A3 (fr) | Nouveaux phenanthridinones substitues et procedes d'utilisation correspondants | |
IL137652A0 (en) | Novel galenic formulations of meloxicam for oral administration | |
GEP20063882B (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
DE69413237D1 (en) | Plättchenaggregationsinhibitoren | |
BG105436A (en) | Pharmaceutical compositions comprising entacapone or nitecapone as well as a cross-linked cellulpse derivative | |
PL348419A1 (en) | Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient | |
BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
HUP0204080A3 (en) | Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them | |
HU9600758D0 (en) | Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption | |
WO2004048381A3 (fr) | Nouveaux composes de pyrazoloazepine utilises en tant qu'agents pharmaceutiques | |
HUP0105426A3 (en) | Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems and pharmaceutical compositions thereof | |
CA2376847A1 (fr) | Complexe d'eletriptan et de derive de cyclodextrine | |
WO2002011740A3 (fr) | Compositions pharmaceutiques renfermant du carbonate de lithium | |
WO2000064427A3 (fr) | Formulation pharmaceutique | |
HUP0401912A3 (en) | Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them | |
MY133957A (en) | "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor" |